MedPath

Use of High Sensitivity Cardiac Troponin in Ruling Out Emergency Patients with Acute Myocardial Injury and Infarction

Completed
Conditions
Acute Coronary Syndrome
Acute Myocardial Infarction
Interventions
Diagnostic Test: Cardiac Troponin Testing
Registration Number
NCT04280926
Lead Sponsor
Hennepin Healthcare Research Institute
Brief Summary

Examine the analytical and clinical performance of Atellica IM TnIH assay for the diagnosis and rule out of acute myocardial injury and myocardial infarction in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication.

Detailed Description

Background: Studies addressing the clinical performance of the Siemens Healthineers High-Sensitivity Troponin I assay (TnIH) on the Atellica IM analyzer for the diagnosis and rule out of acute myocardial injury and myocardial infarction in consecutive patients presenting to a United States (US) emergency department are lacking.

Study objective: Examine the analytical and clinical performance of Atellica IM TnIH assay for the diagnosis and rule out of acute myocardial injury and myocardial infarction in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication.

Hypothesis: The Atellica IM TnIH assay will offer an excellent diagnostic performance for acute myocardial injury and acute myocardial infarction, as well as expedite the risk stratification of patients for early discharge from the emergency department.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1000
Inclusion Criteria
  1. Baseline cTn measurement and at least one additional cTn measurement within 6 hours after initial measurement.
  2. At least one 12-lead electrocardiogram
Exclusion Criteria
  1. Less than 18 years old
  2. Pregnancy
  3. Trauma
  4. Decline to participate
  5. Did not present through the ED
  6. Transferred from an outside hospital or clinic.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CohortCardiac Troponin TestingStudy population: Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
Primary Outcome Measures
NameTimeMethod
Incidence of acute myocardial infarction - Abbott hs-cTnIDay 1

Adjudicated diagnosis of acute myocardial injury using the Abbott hs-cTnI assay

Incidence of myocardial infarction - Roche Gen 5 cTnTDay 1

Adjudicated diagnosis of acute myocardial injury using the Roche Gen 5 cTnT assay

Incidence of myocardial infarction - Abbott contemporary cTnIDay 1

Adjudicated diagnosis of acute myocardial injury using the Abbott contemporary cTnT assay

Secondary Outcome Measures
NameTimeMethod
Number of participants that underwent revascularizationup to 180 days

coronary artery bypass graft surgery or percutaneous coronary intervention

All-cause mortalityup to 180 days

any death

Adjudicated index acute myocardial infarction according to 4th UDMIon admission

acute myocardial infarction, including sub-types following the Fourth Universal Definition of Myocardial Infarction

Safety Outcome - MACE180 days

Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure

Cardiac mortalityup to 180 days

death due to cardiac reasons

Trial Locations

Locations (1)

Hennepin Healthcare Research Institute / Hennepin County Medical Center

🇺🇸

Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath